Trial Profile
Pharmacogenetics in Anti-VEGF Treatment Non-responders Suffering Exudative Age-related Macular Degeneration (AMD): Genetic Correlations and Intraocular Cytokine Concentrations
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- Acronyms RESPONSE
- 24 Oct 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 24 Oct 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
- 17 Oct 2016 Status changed from recruiting to active, no longer recruiting.